Kraft Heinz General Counsel Angel S. Willis resigns effective Oct. 20

Reuters, October 6 - Constellation Brands (STZ.N) reported on Tuesday that its second-quarter profit and sales both exceeded market expectations, thanks to strong demand for its beer products such as Modelo Especial and Victoria, which effectively offset challenges facing the alcohol sector amid weak consumer sentiment. The company also announced that it had acquired SpikedAde, a ready-to-drink (RTD) company with vodka-based products, for at least $75 million, as part of its strategy to expand into new demand segments and strengthen its position in the fast-growing RTD category. Constellation Brands will pay $75 million upon the closing of the SpikedAde deal, and up to an additional $278 million over the next five years, depending on the brand’s performance and the company’s capital allocation priorities. The company’s beer business benefited this year from major sports events, as the FIFA World Cup and NBA Finals boosted viewing parties and social drinking occasions. According to data compiled by London Stock Exchange Group (LSEG), net sales for the quarter ended August 31 rose 6% to $2.63 billion, surpassing analysts’ average estimate of $2.54 billion. Adjusted earnings per share for the quarter were $3.74, above the expected $3.56. The wine and spirits business reported quarterly net sales growth of 17%, while beer increased by 5%. Constellation Brands reaffirmed its fiscal 2027 performance outlook: adjusted earnings per share between $11.20 and $11.90, with organic net sales expected to range from a 1% decline to a 1% increase. The company lowered its annual operating margin forecast from the previous 32%-33% range to between 31% and 32%. Its stock fell 4.5% in after-hours trading, with a year-to-date drop of about 16%. In April, the company withdrew its fiscal 2028 performance outlook, citing a turbulent operating environment and uncertain near-term prospects.

On October 6, the shares of credit scoring giant Fair Isaac (FICO.N) fell 2.4% in after-hours trading, closing at $679.01. The company announced it would cut approximately 15% of its workforce to streamline management, simplify operations, and integrate AI-driven product development. Affected employees started receiving notifications during the week of October 5. The company expects the restructuring plan to be substantially complete by the third quarter of fiscal year 2027. Fair Isaac anticipates a pre-tax charge of around $27 million in the fourth quarter of fiscal year 2026, mainly related to severance packages and employee costs, with most of these expenses expected to result in future cash outflows. By the close of the previous trading day, Fair Isaac’s share price had declined by about 59% year to date. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for readers’ convenience. Reuters is not liable for any damages or losses resulting from the use of the automated translation function.)

Nasdaq notified IB Acquisition on Oct. 5, 2026 it is out of compliance with Listing Rule 5620(a) for missing its annual meeting deadline. Company has 45 days to submit a compliance plan; Nasdaq can grant an exception through March 29, 2027. Letter does not immediately affect the Nasdaq Capital Market listing; shares continue trading under IBAC during the compliance period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IB Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045994), on October 06, 2026, and is solely responsible for the information contained therein.

On October 6th, shares of biotech company Caribou Biosciences (CRBU.O) fell by 36.1% in after-hours trading to $0.73. The company announced it is exploring potential sale, merger, or other options to unlock shareholder value. Caribou plans to discontinue the development of its experimental cell therapy vispa-cel for a certain blood cancer, as well as CB-011 for treating the bone marrow cancer—multiple myeloma. The company stated that vispa-cel is ready for clinical trials, and it has reached an agreement with the FDA on the design for late-stage clinical trials. However, the difficult financing environment for allogeneic CAR-T therapies has made it challenging to raise the necessary funds to advance these projects. Caribou also intends to lay off employees and cut costs; according to its report, as of June 30, 2026, the company held $113.8 million in cash, cash equivalents, and marketable securities. As of the previous trading day’s close, the stock had fallen about 29% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several languages. As automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters assumes no liability for any harm or loss from use of the automated translation feature.)